Synapse functions as an indispensable free drug pipeline database tool for pharmaceutical and biotech sectors, enhancing drug pipelines and marketed drugs by presenting analytical intelligence on a wide range of drug discovery and development.

Fruquintinib is a small molecule drug targeting VEGFR1, VEGFR2, and VEGFR3. This drug was initially developed by Hutchison Whampoa Medicine (Shanghai) Co., Ltd.

The study, titled "Netrin-1 blockade inhibits tumor growth and EMT features in endometrial cancer," presents compelling evidence of the efficacy of a novel anti-Netrin-1 antibody in reducing tumor progression and inhibiting epithelial-to-mesenchymal transition (EMT).

AMPK, which stands for AMP-activated protein kinase, is a key molecule in regulating energy metabolism and is at the core of research into diabetes and other metabolic-related diseases.

Anthrax Vaccine Adsorbed, Adjuvanted, com-mercially known as CYFENDUS, is a preventive vaccine targeting TLR9.

The cGAS-STING signaling pathway is a cytoplasmic DNA sensing pathway that plays a critical role in innate immune responses.

cGAS-STING is a molecular signaling pathway involving two proteins, cyclic GMP-AMP synthase (cGAS) and stimulator of interferon genes (STING).

On August 8, 2023, Bavarian Nordic announced positive top-line results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of its Chikungunya virus candidate vaccine, CHIKV VLP (PXVX0317), in adults and adolescents aged 12 to 64.

The KRAS G12D mutation affects approximately 180,000 patients in the United States and Europe, showing an incidence rate about 2.5 times higher compared to the KRAS G12C mutation.

On August 8, 2023, Vistagen announced the positive top-line results of the PALISADE-2 Phase 3 clinical trial, which assessed the efficacy and safety of its investigational fasedienol (PH94B, Aloradine) nasal spray in adult patients with social anxiety disorder (SAD).

The success of CAR-T in hematologic malignancies lays the foundation for treating solid tumors, and oncology results will provide crucial knowledges for converting CAR-T to other diseases.

the approved dose for BMS's Deucravacitinib treatment of psoriasis is 6mg QD, whereas the estimated dose for TAK279 clinical treatment of psoriasis is over 30mg QD. Why does TAK279 have BIC potential?